In 1998, the ACR Research and Education Foundation (REF) funded a total of $500,000 in grants. This year, the REF funded more than $4.6 million in grants through its core portfolio, which is an increase of over $4 million in funding capabilities in just 10 years. The REF also achieved the distinction of becoming the second largest funding source—just behind the National Institutes of Health (NIH)—of rheumatology research and training programs in the United States and was recently awarded the prestigious four-star rating from Charity Navigator. These achievements could not have been realized without the generous financial support of REF donors.
ACR Delegates Attend AMA House of Delegates Interim Meeting
The 2009 Interim Meeting of the American Medical Association (AMA) House of Delegates was held November 7–10, 2009, in Houston. AMA Delegate Gary Bryant, MD, and AMA Alternate Delegate Eileen Moynihan, MD, represented the ACR.
Letters to the Editor: In Memoriam
One more prescribing rule [See “Rheuminations,” September 2009, p. 6], honored mainly in the breach, in our overspending climate: don’t prescribe an expensive brand when generics are as good or better, especially Nexium (which I have never prescribed) versus omeprazole, Lipitor versus simvastatin (which now costs the VA three cents a pill), and—for rheumatologists who are writing 80% Uloric—allopurinol except for the 10% who might need Uloric.
Philadelphia Displays Many Facets of the Healthcare Debate
City of Brotherly Love displays many facets of the healthcare debate
ACR Online Tools for Learning and Teaching
The ACR is your source for online education
Don’t Get Lost in Translation: Helping rheumatology Patients with Limited English Skills
Helping rheumatology patients with limited English skills
Decoding Autoinflammatory Syndromes
Understanding the genetic basis of errors of the immune system may provide new opportunities for therapy
Is B a Key to Autoimmune Therapy?: B Cell–targeted Therapies in Autoimmune Disease
A perspective on B cell–targeted therapies in autoimmune disease
Best Lupus Treatment Still Up for Debate
Panel looks at decision making for treatment of three high-risk patients
Reading Rheum
Handpicked Reviews of Contemporary Literature
- « Previous Page
- 1
- …
- 748
- 749
- 750
- 751
- 752
- …
- 814
- Next Page »